Merck's Covid Pill Hailed after Cutting Hospitalizations by 50%

Capsules of the experimental antiviral drug Molnupiravir. (AFP)
Capsules of the experimental antiviral drug Molnupiravir. (AFP)
TT

Merck's Covid Pill Hailed after Cutting Hospitalizations by 50%

Capsules of the experimental antiviral drug Molnupiravir. (AFP)
Capsules of the experimental antiviral drug Molnupiravir. (AFP)

US pharmaceutical company Merck said Friday it will seek authorization of its oral drug molnupiravir for Covid-19 after it was shown to reduce the chance newly infected patients were hospitalized by 50 percent.

A simple pill to treat the coronavirus has been sought since the start of the pandemic and Friday's announcement was hailed as a major step towards that goal.

"With these compelling results, we are optimistic that molnupiravir can become an important medicine as part of the global effort to fight the pandemic," said Robert Davis, the company's CEO and president, in a statement.

Anthony Fauci, chief medical advisor to President Joe Biden, told reporters "the data are impressive," and highlighted that the trial results showed there were no deaths among patients who received the drug compared to eight deaths in the placebo group.

The US has procured 1.7 million courses of molnupiravir should it be greenlighted, with the option to buy more, according to Jeff Zients, White House Covid coordinator.

Until now, Covid therapeutics such as monoclonal antibodies and Gilead's remdesivir have been administered intravenously, which holds back their widespread global use.

But experts also cautioned they would like to see the complete underlying data, and stressed that if eventually approved the drug should complement highly effective vaccines, rather than replace them.

Compelling results
In a late stage clinical trial, Merck and its partner Ridgeback Therapeutics evaluated data from around 770 patients -- roughly half of whom received either a five-day course of the pill, while the other received a placebo.

All the patients had lab-confirmed Covid-19 with symptoms that developed within five days of them being assigned to their respective groups.

Of the patients who received molnupiravir, 7.3 percent were hospitalized by day 29, compared to 14.1 percent of those on a placebo -- a relative risk reduction of around 50 percent.

Efficacy was said to hold up against variants of concern, including Delta, in the 40 percent of participants for whom sequencing data was available.

The drug had a good safety profile, with the frequency of adverse events approximately equal between the drug and placebo groups.

The results were compelling enough that an independent data monitoring committee in consultation with the FDA decided to halt the trial early, which could indicate they felt it would be unethical to continue with a placebo arm.

Merck said it plans to submit an application for an Emergency Use Authorization (EUA) to the FDA as soon as possible based on these findings and plans to submit marketing applications to other regulatory bodies worldwide.

Response from the medical community was favorable, with some notes of caution.

Eric Topol, director of the Scripps Research Translational Institute, wrote on Twitter the fact the results were so positive the trial was stopped "would be considered a Eureka moment in the fight against Covid."

But "this is no substitute for vaccination. It's not a miracle cure but a companion tool," tweeted Peter Hotez, dean of Texas Children's Hospital.

Experts also said it would be crucial to administer the drug early for it to be effective. Since it isn't always clear who is at risk for developing severe disease, it would have the greatest impact if it is cheap enough and safe enough to distribute widely.

Broad application
Molnupiravir belongs to a class of antiviral drugs called "polymerase inhibitors," which work by targeting an enzyme that viruses need to copy their genetic material, and introducing mutations that leave them unable to replicate.

"Viruses are basically little machines and they need certain components to replicate themselves," Daria Hazuda, Merck's chief scientific officer of the company's exploratory science center, told AFP in a recent interview. Antivirals disrupt the machinery.

Such drugs are expected to be more variant-proof than monoclonal antibody treatments, which target a surface protein of the virus that is continually evolving.

Molnupiravir was initially developed as an inhibitor of influenza and respiratory syncytial virus, two other important acute respiratory infections, by a team at Emory University.

"If it is proven to be very safe and proven to be effective, then it can be used broadly, irrespective of the diagnosis, to treat and prevent multiple respiratory infections," added Hazuda.



Trump Says Takes ‘Very Seriously’ Possible Iran Threat to Washington

 An aerial view of Washington, DC is seen on October 13. (AFP/Getty Images)
An aerial view of Washington, DC is seen on October 13. (AFP/Getty Images)
TT

Trump Says Takes ‘Very Seriously’ Possible Iran Threat to Washington

 An aerial view of Washington, DC is seen on October 13. (AFP/Getty Images)
An aerial view of Washington, DC is seen on October 13. (AFP/Getty Images)

President Donald Trump said Tuesday that US authorities take "very seriously" any possible threat to Washington, after reports of Iran preparing a so-called dirty bomb plot.

"They will pay a price the likes of which no other country has ever paid before," Trump said, referring to Iran. "We take it very seriously because they happen to be crazy."

Earlier on Tuesday, Iran's Foreign Ministry spokesperson denied a CNN report that it ‌planned to ‌detonate a dirty ‌bomb ⁠in Washington, saying ⁠the allegations were "baseless".

CNN ‌cited ‌sources as saying that US intelligence ‌indicates that Tehran is developing ⁠plans ⁠to potentially detonate a dirty bomb in Washington DC.

Sources familiar with the latest intelligence characterized the Iranian planning as, for now, an effort to give itself options rather than an indicator of an imminent attack, reported CNN. But the plotting picked up by the US has been very specific and includes locations and targets, two of the sources said, and has sparked a flurry of US contingency planning.  

In a statement, White House spokesperson Lauren Bis said that the US is “monitoring any and all potential threats, but at this time there are no credible threats to the homeland.” 


Trump Arrives in Manila for Quad Talks Ahead of China Visit

US President Donald Trump waves as he walks to board Air Force One at Joint Base Andrews, Maryland, on November 16, 2026. (AFP)
US President Donald Trump waves as he walks to board Air Force One at Joint Base Andrews, Maryland, on November 16, 2026. (AFP)
TT

Trump Arrives in Manila for Quad Talks Ahead of China Visit

US President Donald Trump waves as he walks to board Air Force One at Joint Base Andrews, Maryland, on November 16, 2026. (AFP)
US President Donald Trump waves as he walks to board Air Force One at Joint Base Andrews, Maryland, on November 16, 2026. (AFP)

US President Donald Trump arrived in the Philippines on Tuesday at the tail end of a Southeast Asian summit, with protests awaiting him as he prepares for the first meeting in two years of the Quad group of Indo-Pacific countries.

Trump's Asia trip, which includes the Asia-Pacific Economic Cooperation (APEC) forum in Shenzhen and a much-anticipated trilateral meeting with his Chinese and Russian counterparts, comes after his Republican Party's defeat in midterm elections, plus spy allegations and new US curbs on China's access to AI chips that could complicate a fragile trade-war truce.

Demonstrators gathered in Manila for a fifth day of protests that have included the burning of Trump effigies, calls for an end to the Middle East war and scrapping of the US-led Pax Silica supply chain initiative.

Trump arrived late afternoon at the end of the Association of Southeast Asian Nations summit ‌and will join a ‌US-ASEAN "Special Summit" later on Tuesday.

He will first hold a meeting of the Quad – ‌the ⁠US, Japan, Australia and ⁠India – which will be his first and takes place two years after the last gathering of the group, which Trump's predecessor Joe Biden regarded as a signature foreign policy initiative.

It comes ahead of the APEC gathering hosted by Chinese President Xi Jinping, who has previously objected to the Quad as an effort to encircle Beijing. Quad members have said the grouping is not directed against any one country.

QUAD MEETING THE 'BEST POSSIBLE SIGNAL'

At the ASEAN summit on Monday, Chinese Premier Li Qiang hailed what he called "truly extraordinary" economic achievements of China and ASEAN in the face of global trade restrictions, expressing Beijing's commitment to free trade and the need to "stand united, ward off interference, and work together".

China ⁠is ASEAN's largest trading partner and a key source of investment, but the biggest economies ‌of the 11-member bloc – which has a combined GDP of more than $3.9 trillion – ‌want to deepen ties with the US despite protracted trade and diplomatic uncertainty under the Trump administration.

Former US Deputy Secretary of State Kurt ‌Campbell credited Washington's top diplomat, Marco Rubio, with the timing and reconvening of the Quad, which he said had lost ambition ‌under Trump.

"Part of what he (Rubio) is thinking is that this is probably the best possible signal if you're going to go into a trilateral meeting," said Campbell, co-founder of The Asia Group, referring to Thursday's US-China-Russia talks.

"The linchpin of everything that we do in Asia is the US-Japan relationship, and a perception that this is not at the top of the president's mind would concern me."

White House spokesperson Olivia Wales on Friday ‌said that under Trump's leadership, the Quad had demonstrated it is "a partnership of action, tackling the region's toughest challenges and driving opportunities to ensure a free and open Indo-Pacific".

A Japanese foreign ⁠ministry official said it was ⁠expected that Quad leaders would try to show unity, with maritime security, export restrictions, critical-minerals supply-chain diversification and AI among potential discussion points.

Undersea cables, emerging technology and disaster relief were also likely to be covered, a source familiar with the matter said.

JAPAN TO PLAY MORE PROACTIVE ROLE, PM SAYS

ASEAN's leaders held meetings on Tuesday involving counterparts of Japan, South Korea, China and India.

Japanese Prime Minister Sanae Takaichi pledged to work with ASEAN to boost regional economic and energy resilience to address export restrictions and vulnerabilities from rapid AI development, and strengthen supply chains, including on critical minerals.

"While the international order is experiencing a period of great instability, Japan will play an ever more proactive role," Takaichi said.

Trump will sign a joint statement with Thai Prime Minister Anutin Charnvirakul on Tuesday on an agreement on reciprocal trade. Thai media have reported the two would hold talks and the statement would be about progress on negotiations.

The US is Thailand's largest export market, accounting for 24% of its total shipments this year. The US designated Thailand as a major non-NATO ally in 2003.

Trump will on Wednesday meet Ferdinand Marcos Jr, president of US defense ally the Philippines, before heading to Shenzhen.


Pakistan Army Chief and Iran FM Discuss Regional Peace, Security

Vessels at the Strait of Hormuz, as seen from Musandam, Oman, November 17, 2026. (Reuters)
Vessels at the Strait of Hormuz, as seen from Musandam, Oman, November 17, 2026. (Reuters)
TT

Pakistan Army Chief and Iran FM Discuss Regional Peace, Security

Vessels at the Strait of Hormuz, as seen from Musandam, Oman, November 17, 2026. (Reuters)
Vessels at the Strait of Hormuz, as seen from Musandam, Oman, November 17, 2026. (Reuters)

Asim Munir, the powerful army chief of mediating country Pakistan, met with Iranian foreign minister Abbas Araghchi, the Pakistani military said Tuesday, during continued efforts to end the war between the United States and Iran.

Pakistan brokered a June accord that led to a brief halt in fighting between the United States and Iran and set a roadmap for further agreement on reopening the crucial Strait of Hormuz waterway and for negotiations on Tehran's nuclear program.

But the truce collapsed with Washington and Tehran accusing each other of violating the agreement and prompting months of shuttle diplomacy to resuscitate the ceasefire, led principally by mediators Qatar and Pakistan.

During the meeting on Monday, "matters of mutual interest, regional security dynamics and evolving geopolitical developments were discussed," the Pakistani military's media wing said in a statement.

Munir "underscored the importance of sustained engagement, mutual trust and close coordination between the two brotherly countries for promoting regional peace and stability", it added.

Araghchi arrived in Pakistan late on Sunday for a meeting of the Economic Cooperation Organization, a group of nations from Central and South Asia and the Middle East.

Pakistani Foreign Minister Ishaq Dar said on Monday he had held "very candid, very frank" discussions with Araghchi, during the conference confirming that Iran had put forward a two-day proposal to reopen the Strait of Hormuz as part of efforts to end the war with the United States.

He said Washington had not yet responded.

The United States and Israel launched the war on February 28, killing members of Iran's leadership and demanding it cease any nuclear-related activities.

The war plunged the Middle East into violence, with Tehran's retaliatory strikes targeting Gulf countries and sending global energy prices skyrocketing.

Tehran has insisted that Washington meet conditions including the release of frozen assets abroad, sanctions relief and an end to the US naval blockade of Iranian ports in exchange for reopening the Strait of Hormuz.